ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,727.60
-1.08%
S&P ASX All Technology
3,063.80
-1.27%
Brent Oil
80.77
-0.66%
US Dollar vs AUD
1.51126
-0.24%
Bitcoin
67,375.63
-0.81%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immatics NV (IMTX)

  7. Immatics NV (IMTX) News

IMTX

Immatics NV (IMTX)

Immatics NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMTX
DateTimeSourceHeadlineSymbolCompany
14/05/202421:00GlobeNewswire Inc.Immatics Announces First Quarter 2024 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
21/03/202422:00GlobeNewswire Inc.Immatics Announces Full Year 2023 Financial Results and Corporate UpdateNASDAQ:IMTXImmatics NV
23/01/202404:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
20/01/202400:58Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMTXImmatics NV
18/01/202412:30GlobeNewswire Inc.Immatics Announces Pricing of $175 Million Public OfferingNASDAQ:IMTXImmatics NV
18/01/202408:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMTXImmatics NV
18/01/202408:01GlobeNewswire Inc.Immatics Announces Proposed Public OfferingNASDAQ:IMTXImmatics NV
16/01/202420:06PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:IMTXImmatics NV
16/01/202419:59PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:IMTXImmatics NV
30/11/202320:00GlobeNewswire Inc.Levicept Appoints Eliot Forster as CEONASDAQ:IMTXImmatics NV
14/11/202323:00GlobeNewswire Inc.Immatics Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
08/11/202323:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
08/11/202323:00GlobeNewswire Inc.Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialNASDAQ:IMTXImmatics NV
24/10/202322:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
24/10/202322:00GlobeNewswire Inc.Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T MonotherapyNASDAQ:IMTXImmatics NV
14/09/202314:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMTXImmatics NV
14/09/202307:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IMTXImmatics NV
11/09/202321:00GlobeNewswire Inc.Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNASDAQ:IMTXImmatics NV
11/09/202320:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
26/08/202306:11Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IMTXImmatics NV
17/08/202321:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
17/08/202321:00GlobeNewswire Inc.Immatics Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
10/08/202321:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
10/08/202321:00GlobeNewswire Inc.Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid TumorsNASDAQ:IMTXImmatics NV
24/07/202321:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
24/07/202321:00GlobeNewswire Inc.Immatics Announces $35 Million Equity Investment from Bristol Myers SquibbNASDAQ:IMTXImmatics NV
21/06/202306:21Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMTXImmatics NV
16/05/202321:06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMTXImmatics NV
16/05/202321:00GlobeNewswire Inc.Immatics Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
02/05/202321:00GlobeNewswire Inc.Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAMENASDAQ:IMTXImmatics NV
 Showing the most relevant articles for your search:NASDAQ:IMTX

Your Recent History

NYSE
MEL
Mellon
COIN
DIGIIUSD
Digi
BOV
VVRI11
Units
BOV
CPTI11
ConversionPoint
COIN
MATRIXUSD
MatrixSwapToken
BIT
S25052
SG ISSUER
COIN
CLYETH
ASX
TT2HC
Triton Bond Trust in res...
LQID
DIABTC
EU
AUB9L
Amundi Finance Emissions...
TSX
HXQ.U
Global X Nasdaq 100 Inde...
LSE
0M29
Xylem
COIN
MEKBTC
BITMOT
2928143
Gs Group Fx 6.1% Apr34 C...
LSE
MPG
Maypole Group
NASDAQ
NPSN
Naspers
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved